Goldman Sachs Group Inc Sarepta Therapeutics, Inc. Call Options Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$124.33 - $156.75 $7.1 Million - $8.95 Million	57,100 New	57,100 $7.13 Million
Q1 2023 May 14, 2024	BUY	$117.53 - $155.99 $4.28 Million - $5.68 Million	36,400 Added 134.81%	63,400 $8.74 Million
Q1 2023 May 11, 2023	BUY	$117.53 - $155.99 $4.28 Million - $5.68 Million	36,400 Added 134.81%	63,400 $8.74 Million
Q4 2022 May 14, 2024	BUY	$100.86 - $132.13 $2.72 Million - $3.57 Million	27,000 New	27,000 $3.5 Million
Q4 2022 Feb 13, 2023	BUY	$100.86 - $132.13 $2.72 Million - $3.57 Million	27,000 New	27,000 $3.5 Million
Q3 2021 Nov 10, 2021	BUY	$65.97 - $92.48 $3.66 Million - $5.13 Million	55,500 New	55,500 $5.13 Million

528

83.9M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.3B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.